JPMorgan raised the firm’s price target on Ideaya Biosciences to $69 from $65 and keeps an Overweight rating on the shares. The analyst updated models in the SMID-cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target raised to $61 from $53 at RBC Capital
- Biotech Alert: Searches spiking for these stocks today
- Ideaya Biosciences 7.23M share Spot Secondary priced at $35.00
- Ideaya Biosciences Spot Secondary; price range $35.00-$37.00
- Ideaya Biosciences announces $200M common stock offering